<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29107791</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-6017</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>107</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmaceutical sciences</Title>
          <ISOAbbreviation>J Pharm Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Complexes of Felodipine Nanoparticles With Zein Prepared Using a Dual Shift Technique.</ArticleTitle>
        <Pagination>
          <StartPage>239</StartPage>
          <EndPage>249</EndPage>
          <MedlinePgn>239-249</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xphs.2017.09.031</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-3549(17)30695-0</ELocationID>
        <Abstract>
          <AbstractText>To improve the dissolution of felodipine, felodipine-zein complexes were prepared using a dual shift technique, with zein as both stabilizer and carrier. The complexes were characterized by particle size, zeta potential, morphology, crystalline properties, and release behavior. The complexes could be prepared in high yield and showed good redispersibility. The mean diameters of the felodipine particles in complexes were 150-300 nm, with negative zeta potentials of -30 to -25 mV after rehydration, and the particle sizes of the complexes were in the range 10-80 μm. The size of the felodipine nanoparticles incorporated into zein increased gradually with increasing drug content. Powder X-ray diffraction and differential scanning calorimetry indicated that felodipine in the complexes was markedly less crystalline than the pure drug. Both the rate and extent of dissolution of the complexes were significantly greater than those of the active pharmaceutical ingredient or physical mixtures. Spectroscopic analyses indicated that intermolecular interactions, especially hydrophobic interactions, are the major driving forces for the formation of the felodipine nanoparticles and contribute to the stabilization effect. This study provides a promising strategy for enhancing the dissolution rate of drugs using simplified preparation processes and showcases the design of zein-based oral delivery systems for bioactive components.</AbstractText>
          <CopyrightInformation>Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Fuzheng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pharmaceutical Crystal Engineering &amp; Technology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China. Electronic address: fzren@ecust.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Jinping</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pharmaceutical Crystal Engineering &amp; Technology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pharmaceutical Crystal Engineering &amp; Technology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pharmaceutical Crystal Engineering &amp; Technology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Guobin</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pharmaceutical Crystal Engineering &amp; Technology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Haiying</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai SPH New Asia Pharmaceutical Company, Ltd., Shanghai 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jing</LastName>
            <ForeName>Qiufang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Pharmaceutical Crystal Engineering &amp; Technology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharm Sci</MedlineTA>
        <NlmUniqueID>2985195R</NlmUniqueID>
        <ISSNLinking>0022-3549</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011208">Powders</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9010-66-6</RegistryNumber>
          <NameOfSubstance UI="D015028">Zein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002152" MajorTopicYN="N">Calorimetry, Differential Scanning</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011208" MajorTopicYN="N">Powders</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015028" MajorTopicYN="N">Zein</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">complexes</Keyword>
        <Keyword MajorTopicYN="Y">dual shift technique</Keyword>
        <Keyword MajorTopicYN="Y">felodipine</Keyword>
        <Keyword MajorTopicYN="Y">hydrophobic interaction</Keyword>
        <Keyword MajorTopicYN="Y">zein</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29107791</ArticleId>
        <ArticleId IdType="doi">10.1016/j.xphs.2017.09.031</ArticleId>
        <ArticleId IdType="pii">S0022-3549(17)30695-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
